Seer, Inc.
NASDAQ•SEER
執行長: Dr. Omid C. Farokhzad M.D., Ph.D.
板塊: Healthcare
行業: Biotechnology
上市日期: 2020-12-04
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
聯絡資訊
市值
$94.57M
本益比 (TTM)
-1.4
24.5
股息率
--
52周最高
$2.41
52周最低
$1.65
52周範圍
排名54Top 78.1%
2.7
F-Score
改良版 Piotroski 分析
基於 7 年期基本面
疲弱 • 2.7 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2019-2025
深度研究
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料